MTNB Stock Financial Analysis - Matinas BioPharma Holdings, Inc. (NYSEAM) Stock

Overview

Matinas BioPharma Holdings, Inc., based in the United States, operates within the biopharmaceutical industry, focusing primarily on the development of novel therapies for infections that are inadequately addressed by current treatments. The company employs its proprietary lipid nanocrystal (LNC) platform technology to enhance the delivery and bioavailability of lifesaving medications. A key project of Matinas BioPharma is the development of MAT9001, a prescription-only omega-3 fatty acid-based composition, designed to target dyslipidemia and cardiovascular health, which is currently under clinical investigation. Additionally, they are working on formulations for antifungal and antiviral therapies, aiming to tackle serious health issues with innovative lipid-based therapeutic delivery systems. This strategic focus on lipid technology and critical care areas positions Matinas BioPharma as a notable entity in therapeutic advancements.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The operating income for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is -12.20 MM.
The net income for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is -19.61 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-12.20	-19.61
2025-03-31		-16.21	-20.08
2024-12-31		-20.16	-24.25
2024-09-30	0.00	-22.01	-21.13
2024-06-30	0.00	-23.76	-22.91
2024-03-31	0.00	-24.08	-23.25
2023-12-31	1.10	-23.77	-22.94
2023-09-30	2.16	-23.36	-21.26
2023-06-30	3.22	-22.69	-20.67
2023-03-31	4.28	-22.45	-20.53
2022-12-31	3.19	-24.59	-21.00
2022-09-30	2.12	-25.82	-24.06
2022-06-30	1.06	-27.24	-25.44
2022-03-31	-0.00	-26.10	-24.30
2021-12-31	0.03	-24.73	-23.28
2021-09-30	0.10	-24.51	-22.92
2021-06-30	0.19	-23.24	-21.54
2021-03-31	0.19	-24.21	-22.36
2020-12-31	0.16	-24.21	-22.45
2020-09-30	0.10	-23.45	-21.68
2020-06-30

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31	-3.98	-3.98
2024-12-31	-4.98
2024-09-30	-4.52	-4.52
2024-06-30	-5.08	-5.08
2024-03-31	-5.35	-5.35
2023-12-31	-5.28
2023-09-30	-4.90	-4.90
2023-06-30	-4.76	-4.76
2023-03-31	-4.73	-4.73
2022-12-31	-4.84
2022-09-30	-5.54	-5.54
2022-06-30	-5.88	-5.88
2022-03-31	-5.74	-5.74
2021-12-31	-5.63
2021-09-30	-5.71	-5.48
2021-06-30	-5.54	-5.54
2021-03-31	-5.80	-5.80
2020-12-31	-5.90
2020-09-30	-5.99	-6.24
2020-06-30	-6.03	-6.03

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is -11.04 MM.
The cash from investing activities for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is 10.15 MM.
The cash from financing activities for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is 3.20 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-11.04	10.15	3.20
2025-03-31	-12.12	7.21	10.77
2024-12-31	-15.88	9.21	9.17
2024-09-30	-16.95	11.67	9.17
2024-06-30	-17.87	3.11	9.24
2024-03-31	-16.96	12.24	0.05
2023-12-31	-15.28	13.24	-0.01
2023-09-30	-15.00	10.24	-0.01
2023-06-30	-15.55	14.91	-0.01
2023-03-31	-18.49	4.92	-0.02
2022-12-31	-19.16	4.88	0.08
2022-09-30	-18.81	4.98	0.09
2022-06-30	-19.59	-0.53	0.09
2022-03-31	-15.33	10.91	0.27
2021-12-31	-15.22	16.77	6.96
2021-09-30	-15.57	25.80	7.51
2021-06-30	-15.05	22.78	7.57
2021-03-31	-17.35	23.12	7.39
2020-12-31	-17.37	-40.67	48.05
2020-09-30	-17.96	-55.36	47.51
2020-06-30

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/book for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is 0.72.
The p/tbv for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is 0.72.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30		0.72	0.72
2025-03-31	-0.13	0.17	0.19
2024-12-31		0.17	0.18
2024-09-30	-0.78	0.94	1.01
2024-06-30	-1.72	2.75	3.03
2024-03-31	-2.75	3.27	3.52
2023-12-31	-2.22	2.04	2.16
2023-09-30	-1.36	1.01	1.06
2023-06-30	-3.75	2.36	2.46
2023-03-31	-4.68	2.68
2022-12-31		2.81	2.91
2022-09-30		3.39	3.50
2022-06-30	-7.29	3.72	3.82
2022-03-31	-7.54	3.35	3.43
2021-12-31	-9.53	3.75	3.84
2021-09-30	-12.95	4.43	4.53
2021-06-30
2021-03-31	-7.86	2.64	2.69
2020-12-31	-7.67	2.70	2.76
2020-09-30	-7.89	2.51	2.56
2020-06-30	-8.29	2.35	2.39

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is 8.41.
The ebit (3y)/ev for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is 8.87.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	8.41	8.87
2025-03-31	2.80	2.87
2024-12-31	2.76	2.83
2024-09-30	-1.67	-1.66
2024-06-30	-0.60	-0.58
2024-03-31	-0.39	-0.39
2023-12-31	-0.52	-0.56
2023-09-30	-1.12	-1.23
2023-06-30	-0.29	-0.32
2023-03-31	-0.23	-0.25
2022-12-31	-0.25	-0.24
2022-09-30	-0.19	-0.17
2022-06-30	-0.15	-0.14
2022-03-31	-0.15	-0.14
2021-12-31	-0.12	-0.11
2021-09-30	-0.09	-0.08
2021-06-30
2021-03-31	-0.14	-0.12
2020-12-31	-0.14	-0.11
2020-09-30	-0.13	-0.10
2020-06-30	-0.13	-0.10

Management Effectiveness

The roa for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is -0.82.
The roe for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is -1.05.
The roic for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is -2.24.
The croic for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is 0.65.
The ocroic for Matinas BioPharma Holdings, Inc. as of June 30, 2025 is -1.35.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.82	-1.05	-2.24	0.65	-1.35
2025-03-31	-1.08	-1.45	-1.12	0.21	-0.90
2024-12-31	-0.84	-1.10	-1.12	0.21	-0.90
2024-09-30	-0.77	-0.99	-1.03	-0.25	-0.80
2024-06-30	-0.61	-0.71	-1.29	-0.26	-0.94
2024-03-31	-0.51	-0.63	-1.01	-0.09	-0.67
2023-12-31	-0.45	-0.55	-0.79	-0.18	-0.56
2023-09-30	-0.39	-0.48	-0.65	-0.02	-0.49
2023-06-30	-0.39	-0.48	-0.65	-0.02	-0.49
2023-03-31	-0.38	-0.44	-0.56	-0.37	-0.50
2022-12-31	-0.36	-0.41	-0.56	-0.32	-0.44
2022-09-30	-0.38	-0.44	-0.56	-0.32	-0.44
2022-06-30	-0.35	-0.39	-0.54	-0.42	-0.41
2022-03-31	-0.32	-0.35	-0.47	-0.08	-0.29
2021-12-31	-0.32	-0.36	-0.41	0.15	-0.25
2021-09-30	-0.31	-0.32	-0.36	0.28	-0.23
2021-06-30	-0.27	-0.30	-0.32	0.23	-0.23
2021-03-31	-0.27	-0.29	-0.32	0.19	-0.25
2020-12-31	0.56	0.68	-0.33	-0.15	-0.26
2020-09-30	-0.48	-0.57	-0.30	-0.36	-0.25
2020-06-30	-0.43	-0.51	-0.27	-0.29	-0.22

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31	-12.22	-20.93	-21.68
2023-12-31	-5.80	-9.85	-10.82
2023-09-30	-3.69	-6.42	-7.04
2023-06-30	-2.66	-6.42	-7.04
2023-03-31	-4.23	-4.79	-5.24
2022-12-31	-7.02	-11.32	-12.15
2022-09-30	-7.34	-11.32	-12.15
2022-06-30		-23.94	-25.64
2022-03-31	-436.50
2021-12-31	-143.72	-698.51	-742.05
2021-09-30	-64.66	-239.22	-255.75
2021-06-30	-64.66	-112.37	-121.23
2021-03-31	-71.26	-116.65	-126.33
2020-12-31	-89.69	-141.77	-152.88
2020-09-30	-147.73	-226.21	-244.73
2020-06-30